MD-MUSCLE

Medical Device with type I Collagen of porcine origin
Improves muscle and joint mobility



SCAN ME

Medical Device CE (class III). Read the instructions and warnings before use.

COMPOSITION
Collagen of porcine origin, Hypericum, NaCl, Water for injection.

PACKAGE
Box of 5 and 10 vials (single vial 2 ml – extraction volume).

INJECTION ROUTES OF ADMINISTRATION
Intramuscular in the trigger points.

SUGGESTED NEEDLE
Intramuscular: 26G x 16mm needle.
Note: Disinfect the skin thoroughly with iodopovidone or chlorhexidine.

INJECTION TECHNIQUES OF ADMINISTRATION
- **Subcutaneous administration:** insert the needle into the skin overlying the muscle trigger points to a depth of 4-6 mm.
- **Intramuscular administration:** insert the needle into the muscle at a depth of 9-16 mm.

MAIN INDICATIONS
MD-MUSCLE is medical device designed to improve muscle and joint mobility and to reduce pain, counteracting physiological or pathological joint and tissue deterioration.

Scientific evidence shows the efficacy and safety of MD-MUSCLE in cases of:
- **Muscle pain** (acute, subacute, chronic):
  - due to aging
  - due to bad posture
  - due to concomitant chronic diseases
  - due to traumas and injuries.
- Muscle sprains
- Treatment of trigger points.

Treatment can be combined with other therapies.

THERAPEUTIC PROTOCOL:
1 treatment per week: subcutaneous or intramuscular injection into the muscle trigger points of one (2 ml) or two vials (4 ml) per treatment. Results are evident from the third week but, depending on the patient's clinical situation, it is possible to continue treatment up to the tenth week without risk.

REFERENCES
- *Nitecka-Buchta et al. - Comparison between Collagen and Lidocaine Intramuscular Injections in Terms of Their Efficiency in Decreasing Myofascial Pain within Masseter Muscles: A Randomized, Single-Blind Controlled Trial. Pain Research and Management, 2018.*
- *Pavelka K, et al. - Efficacy and tolerability of injectable Collagen-containing Products in comparison to Trimecaine in Patients with acute lumbar spine pain (Study FUTURE-MD-Back Pain). Physiological Research, 2019;68(1):65-74.*
- *Pavelka K, et al. - Chronic Low Back Pain: Current Pharmacotherapeutic Therapies and a New Biological Approach. Current Medicinal Chemistry, 2018.*
- *Reshkova V, et al. - Efficacy and safety evaluation of Guna Collagen MDs injections in knee osteoarthritis – A case series of 30 patients. Physiological Regulating Medicine, 2017; 27-29.*
- *Boshnakov D. Application and assessment of efficacy of collagen injections Guna MDs in gonarthrosis. Physiological Regulating Medicine, 2013:29-30.*
- *Pavelka K, Svobodová R, Jarošová H. MD-Lumbar, MD-Muscle e MD-Neural nella terapia locale del dolore lombare. La Med. Biol., 2012;4:13-7.*

For article consultation: collagenmd.guna.com

INFORMATION RESERVED FOR HEALTHCARE PROFESSIONALS

Medical device CE 0373

IMPATTO ZERO LIFEGATE CO2

Guna S.p.a. has joined Lifegate's Zero® Impact project
To offset its plant's CO_2 emissions by contributing to the development of energy efficiency and forest protection initiatives.

GUNA medical device
Guna S.p.a. • Milano
collagenmd.guna.com

GUNA S.p.a. is a company with quality management standard system ISO 13485 certified by Bureau Veritas Italia SpA

7EX098 B